Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease
Manuel Soto‐Catalán(Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas), Sebastián Mas(Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas)
Cited by 37
Related Papers
Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice
|International Journal of Molecular Sciences|2022|14